Can-Fite BioPharma (NYSE:CANF) Receives Buy Rating from D. Boral Capital

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $11.00 price target on the stock.

Several other analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $2.50 target price on shares of Can-Fite BioPharma in a report on Tuesday, November 4th. Zacks Research raised shares of Can-Fite BioPharma to a “hold” rating in a report on Thursday, November 6th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.75.

Can-Fite BioPharma Price Performance

CANF traded up $0.05 on Tuesday, reaching $0.41. 346,336,073 shares of the stock were exchanged, compared to its average volume of 1,766,893. Can-Fite BioPharma has a fifty-two week low of $0.35 and a fifty-two week high of $2.35. The firm has a market capitalization of $1.45 million, a PE ratio of -0.23 and a beta of 1.01. The company’s 50-day moving average price is $0.53 and its 200 day moving average price is $0.79.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Sabby Management LLC grew its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 80.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,406,050 shares of the company’s stock after purchasing an additional 626,306 shares during the quarter. Can-Fite BioPharma makes up 1.0% of Sabby Management LLC’s investment portfolio, making the stock its 6th largest position. Sabby Management LLC owned approximately 39.72% of Can-Fite BioPharma worth $871,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.